12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Norditropin regulatory update

EMA's CHMP recommended against approving Norditropin somatropin from Novo Nordisk to treat short stature in children with Prader-Willi syndrome. The committee said that the data submitted by Novo Nordisk were insufficient to show...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >